Merck KGaA Buys Bangalore 'Omics Firm
News Oct 30, 2009
Merck KGaA said that it has bought Bangalore Genei (India) Private (BGIP), which makes and sells 'omics tools, through its Merck Specialties subsidiary for an undisclosed sum.
Merck acquired the Bangalore-based firm, which specializes in making and selling genomics and proteomics research products, from the Sanmar Group. The company employs over 100 people and had revenues of around INR202 million ($4.4 million) in fiscal year 2009.
"BGIP's leadership in the Indian academic market, a segment with high growth potential, will ideally complement our existing customer base," Christina Shasserre, global head of Merck's bioscience business, said in a statement. "BGIP's product portfolio comprises a wide range of bioscience products, which are tailored to the needs of the domestic market in India."
Financial terms of the agreement were not released.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.